Skip to content

Fitness for Durable Weight Loss

CPET in the GLP-1 Era
For Weight Reduction, Fitness Is the Modifier

GLP-1 receptor agonists have transformed obesity care, but pharmacotherapy alone leaves three critical gaps

Lean muscle-mass loss
Stagnant cardiorespiratory fitness
Post-discontinuation rebound

CPET gives clinicians a baseline physiologic profile with serial follow-up data, helping calibrate exercise thresholds, monitor Peak VO₂, and track whether microvascular function is improving beyond what the scale shows

Baseline PhysiologySerial TrackingVascular Signals

The GLP-1 Dilemma

The Cost of Unguided Weight Loss

GLP-1s deliver unprecedented weight reduction, but pivotal trials and post-marketing data now show the quality of weight loss matters as much as the quantity

25-40%
of weight lost can include lean mass

In STEP-1, lean mass fell 9.7% while fat mass fell 19.3%. Tirzepatide shows similar or greater body-composition shifts in routine care. Lean-mass preservation is now a practical monitoring issue during rapid pharmacologic weight loss

STEP-1 body-composition substudy; 2025 GLP-1 body-composition meta-analysis

~2/3
of lost weight regained after discontinuation

STEP-1 extension: ~11.6 percentage-points regained within 1 year of stopping semaglutide. SURMOUNT-4: substantial regain across 52 weeks after tirzepatide withdrawal. Maintenance planning needs to begin before the taper

STEP-1 Extension; SURMOUNT-4 randomized withdrawal trial

CRF?
fitness response may not track scale response

Weight loss can improve relative Peak VO₂ partly by lowering the body-weight denominator. CPET helps clinicians separate true cardiorespiratory improvement from scale-driven arithmetic

CKB obesity and serial-CPET framework; AHA CRF scientific statement

“A patient can finish a tele-prescribing intake in eight minutes and have a GLP-1 in hand by evening, without a baseline DEXA, a resistance-training protocol, a titration plan, or a maintenance strategy. Medication is one part of care; the clinical protocol determines whether durable physiology is being built”

The Synergy

Pharmacotherapy + Exercise Outperforms Either Alone

  • Efficacy: Faster weight loss with Zone 2 + GLP-1
  • Safety: Zone 2 may support lower-dose GLP-1 strategies with fewer side effects
  • Pre-conditioning: Starting Zone 2 before GLP-1 therapy can help reduce discontinuation risk and support weight maintenance after stopping
-9.5 kg
Liraglutide + Exercise

vs -6.8 kg liraglutide alone and -4.1 kg exercise alone (RCT, n=195). The combination arm also delivered stronger cardiometabolic outcomes than either component alone

Lundgren et al., NEJM 2021

Serial
Vascular Signal Tracking

Exercise adds a physiologic stimulus that weight loss alone does not provide. Serial CPET tracks whether that stimulus is translating into better Peak VO₂, thresholds, and vascular patterns

CPET-Insight clinical framework

≥ 2 ×/wk
Resistance Training Consensus

JAMA argues GLP-1 weight-loss care should include aerobic and resistance exercise, with coaching, monitoring, and supervision. CPET supplies the aerobic thresholds; body-composition review supplies the muscle signal

Langland, JAMA 2024

Upgrade Standard GLP-1 Practice

Clinical Precision with CPET-Guided Care

Clinical MetricStandard GLP-1 ClinicCPET-Guided Program
Weight-Loss CompositionUp to 40% lean mass loss; sarcopenic-obesity riskMeasured thresholds to guide aerobic dose and support lean-mass preservation alongside clinic-directed strength and nutrition planning
Exercise Prescription"Walk 150 min/week"; age-predicted HR zonesIndividualized four HR zones anchored to AT and modified by IT status when present
Cardiovascular RiskAssumed to improve with weight loss; not measuredSerially tracked: Peak VO₂, O₂-pulse, VE/VCO₂, IT, and exercise BP response
Medication Tolerance / AdherenceDose escalation based mainly on symptoms and scale responseExercise pre-conditioning and serial physiologic feedback to support adherence, maintenance and discontinuation planning
Microvascular FunctionNot assessedInducible Threshold (IT) pattern recognized for clinician review and serial follow-up
Metabolic MonitoringScale weight onlyObjective RER (substrate utilization), AT and ventilatory efficiency
Long-Term MaintenanceUp to 66% rebound after discontinuationSerial Peak VO₂ and threshold tracking to confirm the weight-loss plan is building durable physiology after discontinuation
Patient RelationshipMedication-centered and difficult to differentiateLongitudinal, data-driven, enhanced patient engagement and shared decision making with the patient in the driver's seat

Physiology-Guided Weight Management

Serial CPET Guides the Care Pathway

A clinician-facing pathway from first visit through maintenance planning. Each phase yields documented physiology for the patient, the chart, and clinical decision-making

01

Before or early therapy

Baseline CPET

What physiologic baseline are we trying to improve?

Reviewed Outputs

  • Peak VO₂, AT, IT, O₂-pulse and VE/VCO₂
  • Inducible Threshold (IT) status and exercise BP response
  • Starting phenotype for medication, exercise and body-composition review

02

First prescription cycle

Individualized Exercise Planning

What training dose can this patient actually execute?

Reviewed Outputs

  • Zone 2 mapped to the patient’s AT-IT corridor
  • Customized mix of Continuous Aerobic Exercise Training (CAET) and High-Intensity Interval Training (HIIT) per ExRx
  • Wearable HR targets used to coordinate zone-intensity training sessions

03

Around 3 months

Repeat CPET and Revise

Is the plan building durable physiology beyond the scale?

Reviewed Outputs

  • Change in physiological status is informed by changes in Peak VO₂, AT, IT, O₂-pulse and VE/VCO₂ parameters
  • Peak VO₂ gains of 20% or more can occur in as little as 3 months, and complete IT reversal is also possible - see the example on the Coronary Physiology page
  • ExRx is updated with new HR ranges for Zones 1-4
  • Signal for changing exercise dose, adherence strategy and risk-factor focus

04

Taper and maintenance

Documented Off-Ramp

Is there enough physiologic reserve to support maintenance?

Reviewed Outputs

  • At least one consecutive CPET should show optimized Peak VO₂ with no IT, or stable IT, with or without attaining goal weight
  • Pre-taper review before medication discontinuation is considered. Patient must continue consistent exercise regimen to maintain durable physiology
  • Annual maintenance CPET for goal maintenance and precise longitudinal tracking

For Weight-Loss Clinics

From Prescriber to Metabolic Center of Excellence

Integrating CPET helps convert a medication-only model into a longitudinal clinical program built around measured physiology, patient education, and ongoing clinician review

Clinic Model Shift

A measured physiology program patients can understand and clinics can operationalize

The clinic remains the center of care. CPET-Insight adds interpretive support, repeatable testing structure, and a physiologic record that can guide longitudinal weight-management follow-up

Differentiate Beyond Remote Prescribing

Measured CPET data creates an in-clinic physiology workflow around baseline testing, threshold patterns, and serial Peak VO₂ trajectories

Align With Reimbursable and Cash-Pay Care

CPET (CPT 94621) may support clinical-pathway reimbursement where appropriate, while also fitting premium metabolic packages with recurring reassessment

Keep Patients Engaged With Visible Progress

Serial physiology helps patients see whether fitness, thresholds, and vascular patterns are improving beyond what the scale can show

Add CPET Without Owning the Whole Lab Workflow

CPET-Insight provides protocol guidance, QC review, and physician-founded interpretive support for data acquired at your site or a partner site

CPET-ologist Chatbot Support

Specialized CPET guidance clinics can use at the point of care

The CPET-ologist is a clinician-facing chatbot built around a proprietary clinical knowledge base (CKB). It helps clinics review report findings, translate HR zones into practical follow-up, and answer clinical questions in detail to support decision-making

For Patients

Ask Your Clinic About Baseline CPET

A GLP-1 prescription is a powerful tool. CPET adds a measured baseline and follow-up trajectory so your clinic can review whether fitness, exercise thresholds, and microvascular-function patterns are improving beyond what the scale can show

Three Questions to Bring to Your Next Visit

  1. “What was my baseline Peak VO₂ before I started the medication?” If there is not one, ask whether a CPET would help establish your physiologic baseline
  2. “Is my exercise plan based on my actual ventilatory thresholds, or an age-based formula?” Measured thresholds can make exercise intensity more specific to your physiology
  3. “When will we repeat the CPET to confirm my fitness, muscle, and microvascular-function patterns are improving, not just my weight?” A common reassessment point is around 3 months, with annual tracking once stable

Add Physiologic Decision Support to Weight-Management Care